FILING ANALYSIS · MONDAY, SEPTEMBER 28
NEONC TECHNOLOGIES HOLDINGS, INC. NTHI — 8-K: Regulation FD Disclosure
neutral
The company announced an End-of-Phase 1 Type B meeting with the FDA to discuss the development program for NEO212, including trial design and potential regulatory pathways, but this meeting is routine and does not imply FDA agreement on any aspect of the program.
The filing
8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →